Australia markets close in 43 minutes
  • ALL ORDS

    7,393.50
    +68.30 (+0.93%)
     
  • ASX 200

    7,146.70
    +65.90 (+0.93%)
     
  • AUD/USD

    0.7854
    +0.0006 (+0.08%)
     
  • OIL

    65.23
    +0.33 (+0.51%)
     
  • GOLD

    1,835.00
    +3.70 (+0.20%)
     
  • BTC-AUD

    75,101.16
    +262.48 (+0.35%)
     
  • CMC Crypto 200

    1,563.47
    +127.69 (+8.89%)
     
  • AUD/EUR

    0.6458
    +0.0011 (+0.17%)
     
  • AUD/NZD

    1.0784
    +0.0012 (+0.11%)
     
  • NZX 50

    12,659.01
    -70.91 (-0.56%)
     
  • NASDAQ

    13,719.63
    +105.93 (+0.78%)
     
  • FTSE

    7,129.71
    +53.54 (+0.76%)
     
  • Dow Jones

    34,777.76
    +229.26 (+0.66%)
     
  • DAX

    15,399.65
    +202.95 (+1.34%)
     
  • Hang Seng

    28,497.89
    -112.76 (-0.39%)
     
  • NIKKEI 225

    29,501.55
    +143.73 (+0.49%)
     

Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that members of the executive management team will participate in a fireside chat during the 2021 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20, 2021 at 2:30 p.m. ET.

In order to participate in the audio webcast, interested parties can access the live webcast under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

ABOUT AURINIA

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS™ (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005158/en/

Contacts

Glenn Schulman, PharmD, MPH
SVP, Corporate Communications & IR
gschulman@auriniapharma.com